{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.6","upperLimit":"33.3","value":"29.5"},{"groupId":"OG001","lowerLimit":"38.8","upperLimit":"47.1","value":"42.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"543"},{"groupId":"OG001","value":"538"}],"units":"Participants"}],"description":"PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG001","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population. Number of participants analyzed= participants evaluable for PSA response with PSA value ≥10 ng/mL at baseline and at least one valid post-baseline value.","reportingStatus":"POSTED","timeFrame":"From baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)","title":"Percentage of Participants With PSA Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}